Yusuf IH, Charbel Issa P, Ahn SJ. Hydroxychloroquine-induced retinal toxicity. Front Pharmacol. 2023;14:1196783.

CAS  PubMed  PubMed Central  Google Scholar 

Stokkermans TJ, Falkowitz DM, Trichonas G. Chloroquine and Hydroxychloroquine Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Sep 8]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK537086/. Accessed 8 Sep 2024

US prescribing information: Plaquenil [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/009768s054lbl.pdf. Accessed 8 Sep 2024

go.drugbank.com: Hydroxychloroquine. [Internet]. [cited 2024 Sep 8]. Available from: https://go.drugbank.com/drugs/DB01611. Accessed 8 Sep 2024

Paludetto MN, Kurkela M, Kahma H, Backman JT, Niemi M, Filppula AM. Hydroxychloroquine is metabolized by cytochrome P450 2D6, 3A4, and 2C8, and inhibits cytochrome P450 2D6, while its metabolites also inhibit cytochrome P450 3A in vitro. Drug Metab Dispos. 2023;51(3):293–305.

CAS  PubMed  Google Scholar 

Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–66.

CAS  PubMed  Google Scholar 

Collins KP, Jackson KM, Gustafson DL. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther. 2018;365(3):447–59.

CAS  PubMed  PubMed Central  Google Scholar 

Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(6):1460–9.

CAS  PubMed  Google Scholar 

Andersson NW, Skov L, Andersen JT. Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology. 2021;60(5):2317–26.

CAS  PubMed  Google Scholar 

Chambers CD, Johnson DL, Xu R, Luo Y, Felix R, Fine M, et al. Birth outcomes in women who have taken hydroxycholoroquine during pregnancy: a prospective cohort study. Arthritis Rheumatol. 2022;74(4):711–24.

CAS  PubMed  Google Scholar 

Huybrechts KF, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol. 2021;224(3):290.e1-290.e22.

CAS  PubMed  Google Scholar 

Schreiber K, Giles I, Costedoat-Chalumeau N, Nelson-Piercy C, Dolhain RJ, Mosca M, et al. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. The Lancet Rheumatology. 2023;5(9):e501–6.

CAS  PubMed  Google Scholar 

Russell MD, Dey M, Flint J, Davie P, Allen A, Crossley A, et al. British Society of Rheumatology guideline working group response to European Medicines Agency safety update on Hydroxychloroquine. Rheumatology. 2024;63(2):e37–8.

CAS  PubMed  Google Scholar 

Erkan D, Yazici Y, Harrison MJ, Paget SA. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first-line therapy. Arthritis Rheum. 2002;47(3):285–90.

PubMed  Google Scholar 

Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168–72.

CAS  PubMed  PubMed Central  Google Scholar 

Lenfant T, Costedoat-Chalumeau N. Hydroxychloroquine dose: balancing toxicity and SLE flare risk. Nat Rev Rheumatol. 2023;19(1):6–7.

CAS  PubMed  Google Scholar 

Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365–81.

PubMed  Google Scholar 

Englert KA, Dyduch G, Kłosowicz A, Spałkowska M, Jaworek AK, Migacz-Gruszka K, et al. Cutaneous toll-like receptor 9 pre-defines hydroxychloroquine dosage in patients with both discoid and subacute lupus erythematosus. Medicina. 2023;59(11):2022.

PubMed  PubMed Central  Google Scholar 

Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020;32(3):208–14.

PubMed  PubMed Central  Google Scholar 

Tripp JM, Maibach HI. Hydroxychloroquine-induced retinopathy: a dermatologic perspective. Am J Clin Dermatol. 2006;7(3):171–5.

PubMed  Google Scholar 

Sonigo G, Jachiet M, Bessis D, Cordel N, Faucon C, Petit A, et al. Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: a retrospective multicenter cohort study of 56 patients. J Am Acad Dermatol. 2022;87(1):203–6.

CAS  PubMed  Google Scholar 

Husein-ElAhmed H, Gieler U, Steinhoff M. Lichen planus: a comprehensive evidence-based analysis of medical treatment. Acad Dermatol Venereol. 2019;33(10):1847–62.

CAS  Google Scholar 

Atzmony L, Reiter O, Hodak E, Gdalevich M, Mimouni D. Treatments for cutaneous lichen planus: a systematic review and meta-analysis. Am J Clin Dermatol. 2016;17(1):11–22.

PubMed  Google Scholar 

Xie Y, Xu H, Li C, Wang Y, Lu R, Hua H, et al. Hydroxychloroquine is effective in oral lichen planus: a multicenter, randomized, controlled trial. Oral Dis. 2024;30(5):3126–35.

PubMed  Google Scholar 

Starace M, Brandi N, Alessandrini A, Bruni F, Piraccini BM. Frontal fibrosing alopecia: a case series of 65 patients seen in a single Italian centre. Acad Dermatol Venereol. 2019;33(2):433–8.

CAS  Google Scholar 

Iorizzo M, Tosti A. Frontal fibrosing alopecia: an update on pathogenesis, diagnosis, and treatment. Am J Clin Dermatol. 2019;20(3):379–90.

PubMed  Google Scholar 

Chiang C, Sah D, Cho BK, Ochoa BE, Price VH. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol. 2010;62(3):387–92.

CAS  PubMed  Google Scholar 

Starace M, Cedirian S, Rapparini L, Quadrelli F, Pampaloni F, Bruni F, et al. Enhanced insights into frontal fibrosing alopecia: advancements in pathogenesis understanding and management strategies. Dermatol Ther (Heidelb). 2024;14(6):1457–77.

PubMed  PubMed Central  Google Scholar 

Nic Dhonncha E, Foley CC, Markham T. The role of hydroxychloroquine in the treatment of lichen planopilaris: a retrospective case series and review. Dermatol Ther. 2017;30(3): e12463.

Google Scholar 

Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment. J Am Acad Dermatol. 2020;82(2):283–96.

PubMed  Google Scholar 

Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339–53.

PubMed  Google Scholar 

Singal AK. Porphyria cutanea tarda: recent update. Mol Genet Metab. 2019;128(3):271–81.

CAS  PubMed  Google Scholar 

Singal AK, Kormos-Hallberg C, Lee C, Sadagoparamanujam VM, Grady JJ, Freeman DH, et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2012;10(12):1402–9.

CAS  PubMed  PubMed Central  Google Scholar 

Bansal P, Goyal A, Cusick A, Lahan S, Dhaliwal HS, Bhyan P, et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med. 2021;53(1):117–34.

CAS  PubMed  Google Scholar 

Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386–94.

PubMed  Google Scholar 

Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. Ophthalmology. 2003;110(7):1321–6.

PubMed  Google Scholar 

Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62(6):775–84.

CAS  Google Scholar 

Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22.

PubMed  Google Scholar 

Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453.

PubMed  Google Scholar 

Yam JCS, Kwok AKH. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006;12(4):294–304.

CAS  PubMed  Google Scholar 

Lang GK. Ophthalmology: a short textbook. Stuttgart New York: Thieme; 2007. 586 p. (Thieme flexibook).

Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK, et al. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology. 2015;122(6):1252–6.

PubMed  Google Scholar 

Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med. 1983;75(1):25–34.

CAS  PubMed